IMMUNOVANT, INC. — Net Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/185f9f8b-845e-49e4-86bc-50505f5662db/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-505.6M | 2025-04-01 – 2026-03-31 | evidence 0001764013-26-000064 |
| FY 2024 | $-413.8M | 2024-04-01 – 2025-03-31 | evidence 0001764013-25-000092 |
| FY 2023 | $-259.3M | 2023-04-01 – 2024-03-31 | evidence 0001764013-24-000109 |
| FY 2022 | $-211.0M | 2022-04-01 – 2023-03-31 | evidence 0001764013-23-000065 |
| FY 2021 | $-156.7M | 2021-04-01 – 2022-03-31 | evidence 0001764013-22-000059 |
| FY 2020 | $-107.4M | 2020-04-01 – 2021-03-31 | evidence 0001764013-21-000052 |
| FY 2019 | $-66.4M | 2019-04-01 – 2020-03-31 | evidence 0000950123-20-006444 |
| FY 2018 | $-28.6M | 2018-04-01 – 2019-03-31 | evidence 0000950123-20-006444 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).